IM-1065

N/A

Report date: 2026/03/19 17:03:34

Base Information

Drug NameIM-1065

Drug Alias NameIM-1065IM1065

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsNK cell lectin-like receptor subfamily C member 1 modulatorsAnti-CD3

TargetsEpidermal growth factor receptor erbB1NK cell lectin-like receptor subfamily C member 1T cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsrael

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPurple Biotech Ltd

China Registration ClassN/A

Develop Information

Active CompaniesPurple Biotech Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A